Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 10, 2026, 5:43 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 107 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: salmeterol xinafoate, fluticasone propionate Clear all
Completed Not applicable Interventional Results available

Evaluating Long Acting Beta Agonists Used to Treat Asthma Among Those With Either Arg/Arg or Gly/Gly Genotypes

NCT00521222
View directory record Official record
Conditions
Asthma
Interventions
Fluticasone with salmeterol, Fluticasone HFA, Ipratropium HFA, Albuterol HFA
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
3
States / cities
Hackensack, New Jersey • New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 21, 2023 · Synced Oct 10, 2026, 5:43 AM EDT
Recruiting No phase listed Observational

Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma

NCT00576069
View directory record Official record
Conditions
Asthma
Interventions
budesonide/formoterol, fluticasone/salmeterol, mometasone/formoterol, Prednisone
Drug
Lead sponsor
Gelb, Arthur F., M.D.
Individual
Eligibility
10 Years to 95 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2027
U.S. locations
1
States / cities
Lakewood, California
Source: ClinicalTrials.gov public record
Updated Oct 26, 2023 · Synced Oct 10, 2026, 5:43 AM EDT
Terminated Not applicable Interventional Results available

The Effects of Different Long-acting Bronchodilator Medications on Asthma Patients With Different Genetic Variations

NCT00706446
View directory record Official record
Conditions
Asthma
Interventions
tiotropium bromide, Salmeterol, Formoterol, Fluticasone propionate, budesonide
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 75 Years
Enrollment
255 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 31, 2017 · Synced Oct 10, 2026, 5:43 AM EDT
Completed Phase 4 Interventional Results available

Comparing Fluticasone-salmeterol in Chronic Obstructive Pulmonary Disease (COPD) and Sleep

NCT00731770
View directory record Official record
Conditions
COPD
Interventions
Advair 250, Placebo- matched, Placebo, Advair 250 - matched
Drug
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
45 Years to 75 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 29, 2019 · Synced Oct 10, 2026, 5:43 AM EDT
Completed Phase 4 Interventional Results available

A 12-Month Study Comparing Fluticasone Propionate/Salmeterol (ADVAIR) DISKUS Combination Product 250/50mcg BID To Fluticasone Propionate (FLOVENT) DISKUS 250 mcg BID In Symptomatic Subjects With Asthma

NCT00452699
View directory record Official record
Conditions
Asthma
Interventions
Fluticasone Propionate/salmeterol xinofoate 250/50 mcg BID, Fluticasone propionate 250 mcg BID
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years and older
Enrollment
621 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
58
States / cities
Scottsdale, Arizona • Little Rock, Arkansas • Fountain Valley, California + 48 more
Source: ClinicalTrials.gov public record
Updated Dec 8, 2016 · Synced Oct 10, 2026, 5:43 AM EDT
Completed Phase 3 Interventional Results available

Best African American Response to Asthma Drugs

NCT01967173
View directory record Official record
Conditions
Asthma
Interventions
Flovent Diskus® 100 mcg, Flovent Diskus® 250 mcg, Flovent Diskus® 500 mcg, Advair Diskus® 100/50 mcg, Advair Diskus® 250/50 mcg
Drug
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
5 Years and older
Enrollment
574 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
28
States / cities
Tucson, Arizona • Oakland, California • San Francisco, California + 16 more
Source: ClinicalTrials.gov public record
Updated Nov 15, 2018 · Synced Oct 10, 2026, 5:43 AM EDT
Completed Phase 4 Interventional Results available

The ENERGITO® 2 Study Compares 2 Inhaled Medicines for Chronic Obstructive Pulmonary Disease (COPD). One Medicine is a Combination of Tiotropium and Olodaterol (Stiolto®) Taken Using the Respimat® Inhaler and the Other Medicine is a Combination of Fluticasone and Salmeterol Taken Using the Diskus

NCT03240575
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Tiotropium, Olodaterol, Fluticasone propionate, Salmeterol
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years and older
Enrollment
302 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
45
States / cities
Jasper, Alabama • Flagstaff, Arizona • Fullerton, California + 40 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2020 · Synced Oct 10, 2026, 5:43 AM EDT
Recruiting Phase 4 Interventional

Mechanism(s) of Airflow Limitation During Exacerbation of Asthma

NCT01225913
View directory record Official record
Conditions
Asthma
Interventions
fluticasone/salmeterol in all asthmatics, budesonide/formoterol or fluticasone/salmeterol in all asthmatics
Drug
Lead sponsor
Gelb, Arthur F., M.D.
Individual
Eligibility
10 Years to 80 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2027
U.S. locations
1
States / cities
Lakewood, California
Source: ClinicalTrials.gov public record
Updated Oct 26, 2023 · Synced Oct 10, 2026, 5:43 AM EDT
Completed Phase 3 Interventional Results available

Study Evaluating the 24-Hour Pulmonary Function Profile of Fluticasone Furoate (FF) /GW642444 (Vilanterol) (VI) Inhalation Powder 100/25mcg Once Daily Compared With Fluticasone Propionate/Salmeterol Inhalation Powder 250/50mcg Twice Daily in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

NCT01323621
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Fluticasone Furoate 100mcg/ GW642444 (vilanterol) 25mcg, Fluticasone Propionate 250mcg / salmeterol 50mcg, Double-dummy placebo, Salbutamol as needed
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
512 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
13
States / cities
Jasper, Alabama • Riverside, California • DeLand, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Feb 15, 2018 · Synced Oct 10, 2026, 5:43 AM EDT
Terminated Phase 4 Interventional Results available

Study Of RV-39 In Patients Who Also Have Asthma

NCT00503009
View directory record Official record
Conditions
Asthma
Interventions
fluticasone propionate/salmeterol, fluticasone propionate, placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 40 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Dec 28, 2016 · Synced Oct 10, 2026, 5:43 AM EDT
Completed Phase 4 Interventional

Study Of Patients With Allergic Rhinitis And Asthma

NCT00296530
View directory record Official record
Conditions
Asthma
Interventions
fluticasone propionate/salmeterol, fluticasone propionate, montelukast
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
15 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
80
States / cities
Ozark, Alabama • Tempe, Arizona • Little Rock, Arkansas + 67 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2016 · Synced Oct 10, 2026, 5:43 AM EDT
Completed Phase 3 Interventional Results available

An Efficacy and Safety Study of Fluticasone Furoate/Vilanterol 100/25 Microgram (mcg) Inhalation Powder, Fluticasone Propionate/Salmeterol 250/50 mcg Inhalation Powder, and Fluticasone Propionate 250 mcg Inhalation Powder in Adults and Adolescents With Persistent Asthma

NCT02301975
View directory record Official record
Conditions
Asthma
Interventions
Fluticasone Furoate/Vilanterol 100/25 mcg via ELLIPTA inhaler, Placebo inhalation powders via ELLIPTA inhaler, Fluticasone Propionate/Salmeterol 250/50 mcg via ACCUHALER/DISKUS inhaler, Placebo inhalation powder via ACCUHALER/DISKUS inhaler, Fluticasone Propionate 250 mcg via ACCUHALER/DISKUS inhaler
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years and older
Enrollment
1,526 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
34
States / cities
Huntington Beach, California • Riverside, California • Rolling Hills Estates, California + 30 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2018 · Synced Oct 10, 2026, 5:43 AM EDT
Completed Phase 3 Interventional Results available

Childhood Asthma Research and Education (CARE) Network Trial - Best Add-On Therapy Giving Effective Response (BADGER)

NCT00395304
View directory record Official record
Conditions
Asthma
Interventions
fluticasone propionate + montelukast, fluticasone propionate, fluticasone propionate + salmeterol
Drug
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
6 Years to 18 Years
Enrollment
182 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
5
States / cities
Tucson, Arizona • San Diego, California • Denver, Colorado + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2018 · Synced Oct 10, 2026, 5:43 AM EDT
Recruiting Not applicable Interventional

Boosting Referrals to Asthma Specialists for Patients Seen at the Emergency Room for an Asthma Exacerbation

NCT07396987
View directory record Official record
Conditions
Asthma Attack, Asthma Control, Asthma Exacerbations, Asthma
Interventions
ER-Initiated Telehealth Referral
Behavioral
Lead sponsor
Juan Carlos Cardet
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 10, 2026, 5:43 AM EDT
Completed Phase 4 Interventional

A Study In Pediatric Subjects With Asthma Using ADVAIR HFA, ADVAIR HFA With Spacer, And ADVAIR DISKUS

NCT00400608
View directory record Official record
Conditions
Asthma
Interventions
ADVAIR HFA, ADVAIR DISKUS
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
4 Years to 11 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
3
States / cities
Huntington Beach, California • Long Beach, California • Medford, Oregon
Source: ClinicalTrials.gov public record
Updated Oct 28, 2016 · Synced Oct 10, 2026, 5:43 AM EDT
Completed Phase 2 Interventional Results available

Evaluation of Dupilumab's Effects on Airway Inflammation in Patients With Asthma

NCT02573233
View directory record Official record
Conditions
Asthma
Interventions
Placebo, Dupilumab SAR231893/REGN668, fluticasone propionate and salmeterol, budesonide and formoterol, mometasone furoate and formoterol
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 65 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
6
States / cities
Tucson, Arizona • Denver, Colorado • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 4, 2022 · Synced Oct 10, 2026, 5:43 AM EDT
Completed Phase 3 Interventional Results available

A Phase III Parallel Group Study, Comparing the Efficacy, Safety and Tolerability of the Fixed Dose Combination (FDC) of Fluticasone Furoate+Umeclidinium Bromide+Vilanterol (FF/UMEC/VI) With the FDC of FF/VI in Subjects With Inadequately Controlled Asthma

NCT02924688
View directory record Official record
Conditions
Asthma
Interventions
FF/UMEC/VI (100/31.25/25) mcg, FF/UMEC/VI (100/62.5/25) mcg, FF/UMEC/VI (200/31.25/25) mcg, FF/UMEC/VI (200/62.5/25) mcg, FF/VI (100/25) mcg, FF/VI (200/25) mcg, Fluticasone/salmeterol (FSC), Albuterol/salbutamol, ELLIPTA DPI, DISKUS DPI, METERED-DOSE INHALER (MDI)
Drug · Device
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
2,436 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
99
States / cities
Birmingham, Alabama • Mobile, Alabama • Montgomery, Alabama + 89 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2021 · Synced Oct 10, 2026, 5:43 AM EDT
Completed Phase 4 Interventional Results available

A 24-Week Study to Evaluate the Safety and Efficacy of ADVAIR DISKUS® Inhaler 250/50mcg Plus SPIRIVA HANDIHALER® Inhaler Versus SPIRIVA HANDIHALER® Inhaler Plus Placebo DISKUS® Inhaler in Subjects With Chronic Obstructive Pulmonary Disease (COPD).

NCT00784550
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Tiotropium Bromide, Fluticasone Propionate/Salmeterol
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years to 99 Years
Enrollment
342 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
35
States / cities
Riverside, California • Fort Collins, Colorado • Clearwater, Florida + 31 more
Source: ClinicalTrials.gov public record
Updated Nov 23, 2016 · Synced Oct 10, 2026, 5:43 AM EDT
Completed Phase 3 Interventional Results available

HZA113091 Efficacy and Safety of Fluticasone Furoate/Vilanterol (GW642444) in Adults and Adolescents

NCT01147848
View directory record Official record
Conditions
Asthma
Interventions
Fluticasone furoate/Vilanterol Inhalation Powder, Fluticasone propionate/salmeterol Inhalation Powder, Placebo (1), Placebo (2)
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years and older
Enrollment
810 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
25
States / cities
Huntington Beach, California • Los Angeles, California • Riverside, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jan 18, 2017 · Synced Oct 10, 2026, 5:43 AM EDT
Completed Phase 4 Interventional

Non-invasive Measures of Distal Lung Disease in Asthmatics

NCT00250341
View directory record Official record
Conditions
Asthma
Interventions
QVAR, Advair, Servent Diskus
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Dec 2, 2021 · Synced Oct 10, 2026, 5:43 AM EDT
Completed Phase 4 Interventional

Chronic Obstructive Pulmonary Disease Endpoints Study

NCT00358358
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Fluticasone Propionate/Salmeterol 500/50mcg combination, Fluticasone Propionate 500mcg, Salmeterol 50mcg
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
163 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
4
States / cities
Absecon, New Jersey • Charleston, South Carolina • Greenville, South Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 20, 2017 · Synced Oct 10, 2026, 5:43 AM EDT
Completed Phase 4 Interventional Results available

Study Of Fluticasone Propionate/Salmeterol In Asthmatic Subjects

NCT00517634
View directory record Official record
Conditions
Asthma
Interventions
FP, SFC, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 55 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 16, 2016 · Synced Oct 10, 2026, 5:43 AM EDT
Completed Phase 3 Interventional Results available

DISKUS vs. ELLIPTA Device Preference Study in Chronic Obstructive Pulmonary Disease (COPD)

NCT01868009
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
ELLIPTA, DISKUS
Device
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
287 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
17
States / cities
Jasper, Alabama • Riverside, California • Clearwater, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2014 · Synced Oct 10, 2026, 5:43 AM EDT
Completed Phase 4 Interventional Results available

The Leukotriene Modifier Or Corticosteroid or Corticosteroid-Salmeterol Trial

NCT00156819
View directory record Official record
Conditions
Asthma
Interventions
fluticasone, montelukast, Fluticasone plus salmeterol
Drug
Lead sponsor
JHSPH Center for Clinical Trials
Other
Eligibility
6 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
19
States / cities
Birmingham, Alabama • Denver, Colorado • Jacksonville, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Dec 9, 2015 · Synced Oct 10, 2026, 5:43 AM EDT